
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is currently facing some challenges with their latest clinical trial data, however, their overall approach using their DDX platform is still promising, as demonstrated by the positive preclinical data on polidocanol for enhancing urothelial transfection. Additionally, their strong cash position of $285.2 million and management's decisions to conserve capital and re-evaluate their clinical trial strategy show responsible financial management. While the updated interim data for the LEGEND Phase 2 trial of detalimogene in NMIBC is concerning, enGene Therapeutics remains a solid investment opportunity with a potential role in the treatment of high-risk non-muscle invasive bladder cancer.
Bears say
enGene Therapeutics is focused on developing a gene therapy treatment for bladder cancer, but the company is facing challenges in the near-term with a lackluster data update and uncertainty surrounding the future of its CMO. There are also doubts about whether the company's treatment can achieve a competitive profile, with a current estimate for the 12-month complete response rate sitting at 24.5%. With these concerns in mind, our outlook on the company's stock is negative, and we have downgraded it to Neutral with a $4/sh PT.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares